Amalgamated Bank Sells 1,001 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Amalgamated Bank decreased its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 6.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 14,870 shares of the company’s stock after selling 1,001 shares during the quarter. Amalgamated Bank’s holdings in Inari Medical were worth $613,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Bamco Inc. NY boosted its holdings in shares of Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock worth $37,288,000 after acquiring an additional 167,000 shares during the period. Lighthouse Investment Partners LLC acquired a new position in Inari Medical in the 2nd quarter valued at $2,145,000. Integral Health Asset Management LLC grew its holdings in Inari Medical by 100.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after buying an additional 200,000 shares in the last quarter. Seven Eight Capital LP bought a new position in Inari Medical during the 1st quarter worth $499,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after buying an additional 364,983 shares in the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Mitch C. Hill sold 3,000 shares of Inari Medical stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares in the company, valued at $8,105,348. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now directly owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 126,000 shares of company stock valued at $5,921,390. Company insiders own 10.60% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective for the company. Leerink Partners started coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price target for the company. Stifel Nicolaus began coverage on Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective on the stock. Canaccord Genuity Group upped their target price on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Finally, William Blair assumed coverage on Inari Medical in a research report on Thursday, July 25th. They issued an “outperform” rating on the stock. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Inari Medical presently has an average rating of “Hold” and an average price target of $58.89.

Inari Medical Stock Performance

NASDAQ:NARI opened at $50.56 on Friday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -37.45 and a beta of 0.96. The firm has a 50-day moving average price of $45.19 and a two-hundred day moving average price of $46.94. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.